Market Cap | 12.98M | P/E | - | EPS this Y | 20.60% | Ern Qtrly Grth | - |
Income | -38.37M | Forward P/E | -0.19 | EPS next Y | 56.20% | 50D Avg Chg | -10.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -16.00% |
Dividend | N/A | Price/Book | 0.68 | EPS next 5Y | - | 52W High Chg | -77.00% |
Recommedations | 2.00 | Quick Ratio | 1.79 | Shares Outstanding | 16.43M | 52W Low Chg | 66.00% |
Insider Own | 1.52% | ROA | -63.74% | Shares Float | 15.34M | Beta | 2.36 |
Inst Own | 7.57% | ROE | -355.35% | Shares Shorted/Prior | 1.23M/0.98M | Price | 1.00 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 51,474 | Target Price | 6.50 |
Oper. Margin | - | Earnings Date | May 10 | Volume | 121,900 | Change | -2.91% |
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
HC Wainwright & Co. | Buy | Apr 1, 24 |
HC Wainwright & Co. | Buy | Mar 6, 24 |
HC Wainwright & Co. | Buy | Feb 7, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Dunne Michael W. | Director Director | Dec 22 | Buy | 1.40 | 25,000 | 35,000 | 113,754 | 12/27/23 |
Dunne Michael W. | Director Director | Nov 22 | Buy | 2.0345 | 20,000 | 40,690 | 78,754 | 11/27/23 |
Fishman Corey N. | Chief Executive Offi.. Chief Executive Officer | Nov 20 | Buy | 1.5863 | 10,000 | 15,863 | 54,449 | 11/20/23 |
Hecht Beth | Director Director | Jun 15 | Option | 0.00 | 15,853 | 18,839 | 06/15/23 | |
Dunne Michael W. | Director Director | Jun 15 | Option | 0.00 | 15,853 | 53,488 | 06/15/23 | |
Chin Mark | Director Director | Jun 15 | Option | 0.00 | 15,853 | 18,306 | 06/15/23 | |
Dunne Michael W. | Director Director | Apr 01 | Option | 0.00 | 1,299 | 37,635 | 06/05/23 | |
HUNT RONALD | Director Director | Apr 01 | Option | 0.00 | 2,041 | 6,071 | 04/03/23 | |
Ahrens Brenton Karl | Director Director | Sep 08 | Sell | 2.3 | 33,298 | 76,585 | 82,246 | 09/12/22 |
Dunne Michael W. | Director Director | Sep 07 | Buy | 2.22 | 10,000 | 22,200 | 35,576 | 09/09/22 |
Hecht Beth | Director Director | Jun 23 | Option | 0.00 | 36,798 | 44,805 | 06/24/22 | |
Dunne Michael W. | Director Director | Mar 25 | Option | 0.00 | 10,494 | 346,849 | 03/29/22 | |
Hecht Beth | Director Director | Mar 18 | Option | 0.00 | 7,642 | 8,007 | 03/22/22 | |
Matthews Judith M. | Chief Financial Offi.. Chief Financial Officer | Mar 11 | Sell | 0.31 | 63,340 | 19,635 | 65,292 | 03/15/22 |